|
Synonyms: TQJ-230 | TQJ230
Compound class:
Nucleic acid
Comment: Pelacarsen (TQJ230) is an apolipoprotein A synthesis reducer. It is a liver-targeted antisense oligonucleotide that was designed to lower serum lipoprotein A as a mechanism to reduce atherosclerotic cardiovascular disease risk [1-2].
We have been unable to locate a full chemical SMILES for the drug, or its HELM notation. We provide the basic nucleic acid structure for the molecule here. Full specifications for all modifications are available from its INN record. |
Classification  |
|
| Compound class | Nucleic acid |
| Compound subclass | Antisense oligonucleotide (ASO) |
| Target | apolipoprotein A |
| International Nonproprietary Names |
|
| INN number | INN |
| 11187 | pelacarsen |
| Synonyms |
| TQJ-230 | TQJ230 |
| Database Links |
|
| CAS Registry No. | 1637637-70-7 (source: who inn RECORD) |
| GtoPdb PubChem SID | 507750344 |
| Search PubMed clinical trials | pelacarsen |
| Search PubMed titles | pelacarsen |
| Search PubMed titles/abstracts | pelacarsen |
